- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Multiple sclerosis (MS) related spasticity
- Meeting Date: March 2020
- Public Summary Document (PSD) March 2020 PBAC Meeting - (PDF 831KB)
- Public Summary Document (PSD) March 2020 PBAC Meeting - (Word 167KB)
Nabiximols – March 2020
Nabiximols: Oromucosal spray, 8 mg per dose, 90 doses; Sativex®
Last updated
3 July 2020